Naltrexone for Relapse Prevention - Full Text View

Naltrexone for Relapse Prevention

This study has been completed.

Sponsored by:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ClinicalTrials.gov Identifier:	NCT00000442

Purpose

This study is to evaluate the safety and effectiveness of an injectable slow releasing preparation of naltrexone to reduce alcohol consumption and risk of relapse in alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo injection for a total of three months, with two subsequent followup visits spanning a 6- month period.

Condition	Intervention	Phase
Alcoholism	Drug: naltrexone (Revia)	Phase IV

MedlinePlus related topics:

Alcoholism

Drug Information available for:

Naltrexone Naltrexone hydrochloride Ethanol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Etiology and Treatment of Alcohol Dependence

Further study details as provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):

Estimated Enrollment:	57
Estimated Study Completion Date:	December 2002

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Meets criteria for alcohol dependence.
Abstinent from alcohol for a period of at least 3 days prior to beginning of study.
Able to read English and complete study evaluations.
Females who are postmenopausal, have had surgical sterilization, or use reliable means of birth control.

Exclusion Criteria:

Meets criteria for dependence on a psychoactive substance other than alcohol and nicotine and/or cannabis.
Prior history of opioid dependence.
Regular use of psychoactive drugs including anxiolytics and antidepressants.
Prior treatment with naltrexone.
Current use of disulfiram.
Psychotic or otherwise severely psychiatrically disabled (e.g., suicidal, current mania).
Significant underlying medical conditions such as hepatic, cerebral, renal, thyroid, or cardiac disease.
Abstinent longer than 28 days prior to randomization.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000442

Locations


United States, Connecticut
	Department of Psychiatry, University of Connecticut
	Farmington, Connecticut, United States, 06030

Sponsors and Collaborators

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

More Information

Study ID Numbers:	NIAAAKRA3510
First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000442
Health Authority:	United States: Federal Government